Patient P-02018
Synthetic patientMETA-24 · Day 168 · 25–34 · M · baseline S01Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
74%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S01
- Day 65 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 80 GI-04 recommended — GI Support Protocol GI-04
- Day 81 Patient accepted — Started GI-04 in the companion
- Day 85 ME-01 recommended — Monitoring Escalation ME-01
- Day 86 Patient accepted — Started ME-01 in the companion
- Day 89 GI symptom burden −25% vs expected — GI Support Protocol GI-04
- Day 89 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 95 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 65.
Primary contributors, last 14 days
- Nutritional resilience-11
- GI instability+10
- Toxicity+7
- Inflammatory activity+6
What helped?
- GI Support Protocol GI-04Day 80Result: symptom burden −25%
- Monitoring Escalation ME-01Day 85Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
59%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 69% showed improvement
- median effect visible after 6 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable44 min
worsening · -3.0 vs previous 14 d
Sleep duration
Wearable6.3 h
stable · +0.2 vs previous 14 d
Energy level
Daily log3.4/10
stable · -0.1 vs previous 14 d
Steps
Wearable4,651
stable · -148 vs previous 14 d
GI burden
Companion62.3/100
worsening · +7.1 vs previous 14 d
Adherence
Companion49.5 %
stable · -0.0 vs previous 14 d
Sleep quality
Wearable35.3/100
stable · +0.8 vs previous 14 d
Glucose, CGM daily mean
CGM146 mg/dL
stable · +1.1 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 25 from the failing basin, 66 from restoration.
Would help
- NP-02 Dietary Support Protocol59% improved among 32 similar · onset 10 d · confidence 68%
- SC-12 Supportive Compound69% improved among 26 similar · onset 6 d · confidence 68%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 68%
- More proteinGI -3.5 next day on high-intake days · n 19
Would not help
- Keep histamine lowGI +3.9 next day on high-intake days · n 20
- Keep fat lowGI +3.1 next day on high-intake days · n 17
- Keep ultra-processed lowGI +3.1 next day on high-intake days · n 23
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+3.9detractor · 95%
- Protein-3.5supporter · 95%
- Dietary fat load+3.1detractor · 95%
- Ultra-processed food+3.1detractor · 95%
- Alcohol+2.5detractor · 87%
- Insoluble fibre+1.9detractor · 63%
- Simple carbohydrates+1.7no signal · 53%
- Caffeine-1no signal · 35%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 62 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 40/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 59
- Autonomic recovery ↓45
- WearableResting HR 83 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 44
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 2.8 · butyrate capacity 40/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 44 ms
- Sleep
- 6.5 h
- Steps
- 4,671
- Resting HR
- 82 bpm
Daily log: GI score 62, nutritional resilience 34, adherence 50.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02093 | 20% | S05 | AD-05 | no change | 40 |
| P-02483 | 23% | S06 | BR-03 | no change | 64 |
| P-02087 | 21% | S01 | BR-03 | no change | 40 |
| P-02151 | 36% | S04 | CR-01 | improved | 49 |
| P-02054 | 35% | S01 | CR-01 | improved | 57 |
| P-02025 | 34% | S15 | CR-01 | improved | 61 |
| P-02009 | 33% | S08 | CR-01 | improved | 64 |
| P-02154 | 31% | S16 | CR-01 | improved | 57 |
| P-02233 | 30% | S16 | CR-01 | improved | 66 |
| P-02395 | 23% | S12 | DT-01 | improved | 57 |
| P-02491 | 22% | S09 | DT-01 | no change | 65 |
| P-02274 | 21% | S15 | DT-01 | improved | 50 |